GENEVA (Reuters) – The World Health Organization’s vaccine safety panel said on Friday that data from AstraZeneca’s COVID-19 shot do not point to any overall increase in clotting conditions but it would continue to monitor its effects.
“The AstraZeneca COVID-19 vaccine (including Covishield) continues to have a positive benefit-risk profile, with tremendous potential to prevent infections and reduce deaths across the world,” the WHO’s global advisory committee on vaccine safety said in a statement issued after its independent experts met on Tuesday and on Thursday to review data.
(Reporting by Michael Shields in Zurich; editing by Stephanie Nebehay)
